表紙
市場調查報告書

鼻腔給藥技術的全球市場

Nasal Drug Delivery Technology

出版商 Global Industry Analysts, Inc. 商品編碼 908487
出版日期 內容資訊 英文 278 Pages
商品交期: 最快1-2個工作天內
價格
鼻腔給藥技術的全球市場 Nasal Drug Delivery Technology
出版日期: 2020年09月01日內容資訊: 英文 278 Pages
簡介

本報告提供全球鼻腔給藥技術市場相關調查分析,提供市場概要,主要企業,市場趨勢·促進因素,全球市場預測,各地區市場分析,競爭情形相關的系統性資訊。

第1章 調查手法

第2章 摘要整理

  • 市場概要
    • 全球競爭企業的市場佔有率
  • 主要企業
  • 市場趨勢·促進因素
  • 全球市場預測

第3章 市場分析

  • 各地區市場分析
    • 美國
    • 加拿大
    • 日本
    • 中國
    • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 其他的歐洲
    • 亞太地區
    • 其他全球地區

第4章 競爭

  • 3M COMPANY
  • AEGIS THERAPEUTICS
  • APTARGROUP
  • ASTRAZENECA PLC
  • GLAXOSMITHKLINE PLC
  • JOHNSON & JOHNSON
  • MERCK & CO.
  • NOVARTIS INTERNATIONAL AG
  • PFIZER

第5章 相關調查

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP13533

Global Nasal Drug Delivery Technology Market to Reach $73.3 Billion by 2027

Amid the COVID-19 crisis, the global market for Nasal Drug Delivery Technology estimated at US$51.6 Billion in the year 2020, is projected to reach a revised size of US$73.3 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. Nasal Sprays, one of the segments analyzed in the report, is projected to record a 6.2% CAGR and reach US$40 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Drops & Liquids segment is readjusted to a revised 4.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $15.2 Billion, While China is Forecast to Grow at 4.8% CAGR

The Nasal Drug Delivery Technology market in the U.S. is estimated at US$15.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$12.9 Billion by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Other Dosage Forms Segment to Record 2.5% CAGR

In the global Other Dosage Forms segment, USA, Canada, Japan, China and Europe will drive the 2.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$4.2 Billion in the year 2020 will reach a projected size of US$5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$8.4 Billion by the year 2027.We bring years of research experience to this 7th edition of our report. The 278-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • 3M Company
  • Aegis Therapeutics LLC
  • Aptargroup, Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Global Competitor Market Shares
    • Nasal Drug Delivery Technology Competitor Market Share Scenario Worldwide (in %): 2019 &
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Nasal Drug Delivery Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 2: World Historic Review for Nasal Drug Delivery Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 3: World 15-Year Perspective for Nasal Drug Delivery Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Nasal Sprays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 5: World Historic Review for Nasal Sprays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 6: World 15-Year Perspective for Nasal Sprays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Drops & Liquids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 8: World Historic Review for Drops & Liquids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 9: World 15-Year Perspective for Drops & Liquids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 11: World Historic Review for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 12: World 15-Year Perspective for Other Dosage Forms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Multi-dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 14: World Historic Review for Multi-dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 15: World 15-Year Perspective for Multi-dose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Unit-dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 17: World Historic Review for Unit-dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 18: World 15-Year Perspective for Unit-dose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Bi-dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 20: World Historic Review for Bi-dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 21: World 15-Year Perspective for Bi-dose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Allergic & Non-allergic Rhinitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 23: World Historic Review for Allergic & Non-allergic Rhinitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 24: World 15-Year Perspective for Allergic & Non-allergic Rhinitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Nose Congestion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 26: World Historic Review for Nose Congestion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 27: World 15-Year Perspective for Nose Congestion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Vaccination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 29: World Historic Review for Vaccination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 30: World 15-Year Perspective for Vaccination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Other Therapeutic Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 32: World Historic Review for Other Therapeutic Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 33: World 15-Year Perspective for Other Therapeutic Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Home Care Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 35: World Historic Review for Home Care Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 36: World 15-Year Perspective for Home Care Settings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 38: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 39: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • Market Facts & Figures
    • US Nasal Drug Delivery Technology Market Share (in %) by Company: 2019 &
    • Market Analytics
    • TABLE 40: USA Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 41: USA Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 42: USA 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027
    • TABLE 43: USA Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 44: USA Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 45: USA 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027
    • TABLE 46: USA Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 47: USA Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 48: USA 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027
    • TABLE 49: USA Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 50: USA Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 51: USA 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 52: Canada Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 53: Canada Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 54: Canada 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027
    • TABLE 55: Canada Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 56: Canada Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 57: Canada 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027
    • TABLE 58: Canada Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 59: Canada Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 60: Canada 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027
    • TABLE 61: Canada Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 62: Canada Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 63: Canada 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 64: Japan Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 65: Japan Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 66: Japan 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027
    • TABLE 67: Japan Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 68: Japan Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 69: Japan 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027
    • TABLE 70: Japan Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 71: Japan Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 72: Japan 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027
    • TABLE 73: Japan Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 74: Japan Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 75: Japan 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 76: China Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 77: China Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 78: China 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027
    • TABLE 79: China Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 80: China Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 81: China 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027
    • TABLE 82: China Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 83: China Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 84: China 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027
    • TABLE 85: China Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 86: China Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 87: China 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027
  • EUROPE
    • Market Facts & Figures
    • European Nasal Drug Delivery Technology Market: Competitor Market Share Scenario (in %) for 2019 &
    • Market Analytics
    • TABLE 88: Europe Current & Future Analysis for Nasal Drug Delivery Technology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 89: Europe Historic Review for Nasal Drug Delivery Technology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 90: Europe 15-Year Perspective for Nasal Drug Delivery Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 91: Europe Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 92: Europe Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 93: Europe 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027
    • TABLE 94: Europe Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 95: Europe Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 96: Europe 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027
    • TABLE 97: Europe Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 98: Europe Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 99: Europe 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027
    • TABLE 100: Europe Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 101: Europe Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 102: Europe 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 103: France Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 104: France Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 105: France 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027
    • TABLE 106: France Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 107: France Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 108: France 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027
    • TABLE 109: France Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 110: France Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 111: France 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027
    • TABLE 112: France Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 113: France Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 114: France 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 115: Germany Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 116: Germany Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 117: Germany 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027
    • TABLE 118: Germany Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 119: Germany Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 120: Germany 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027
    • TABLE 121: Germany Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 122: Germany Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 123: Germany 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027
    • TABLE 124: Germany Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 125: Germany Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 126: Germany 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 127: Italy Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 128: Italy Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 129: Italy 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027
    • TABLE 130: Italy Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 131: Italy Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 132: Italy 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027
    • TABLE 133: Italy Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 134: Italy Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 135: Italy 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027
    • TABLE 136: Italy Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 137: Italy Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 138: Italy 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 139: UK Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 140: UK Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 141: UK 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027
    • TABLE 142: UK Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 143: UK Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 144: UK 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027
    • TABLE 145: UK Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 146: UK Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 147: UK 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027
    • TABLE 148: UK Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 149: UK Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 150: UK 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 151: Rest of Europe Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 152: Rest of Europe Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 153: Rest of Europe 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027
    • TABLE 154: Rest of Europe Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 155: Rest of Europe Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 156: Rest of Europe 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027
    • TABLE 157: Rest of Europe Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 158: Rest of Europe Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 159: Rest of Europe 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027
    • TABLE 160: Rest of Europe Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 161: Rest of Europe Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 162: Rest of Europe 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 163: Asia-Pacific Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 164: Asia-Pacific Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 165: Asia-Pacific 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027
    • TABLE 166: Asia-Pacific Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 167: Asia-Pacific Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 168: Asia-Pacific 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027
    • TABLE 169: Asia-Pacific Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 170: Asia-Pacific Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 171: Asia-Pacific 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027
    • TABLE 172: Asia-Pacific Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 173: Asia-Pacific Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 174: Asia-Pacific 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 175: Rest of World Current & Future Analysis for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 176: Rest of World Historic Review for Nasal Drug Delivery Technology by Dosage Form - Nasal Sprays, Drops & Liquids and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 177: Rest of World 15-Year Perspective for Nasal Drug Delivery Technology by Dosage Form - Percentage Breakdown of Value Sales for Nasal Sprays, Drops & Liquids and Other Dosage Forms for the Years 2012, 2020 & 2027
    • TABLE 178: Rest of World Current & Future Analysis for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 179: Rest of World Historic Review for Nasal Drug Delivery Technology by System - Multi-dose, Unit-dose and Bi-dose Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 180: Rest of World 15-Year Perspective for Nasal Drug Delivery Technology by System - Percentage Breakdown of Value Sales for Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 & 2027
    • TABLE 181: Rest of World Current & Future Analysis for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 182: Rest of World Historic Review for Nasal Drug Delivery Technology by Therapeutic Application - Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 183: Rest of World 15-Year Perspective for Nasal Drug Delivery Technology by Therapeutic Application - Percentage Breakdown of Value Sales for Allergic & Non-allergic Rhinitis, Nose Congestion, Vaccination and Other Therapeutic Applications for the Years 2012, 2020 & 2027
    • TABLE 184: Rest of World Current & Future Analysis for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 185: Rest of World Historic Review for Nasal Drug Delivery Technology by End-Use - Home Care Settings and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 186: Rest of World 15-Year Perspective for Nasal Drug Delivery Technology by End-Use - Percentage Breakdown of Value Sales for Home Care Settings and Hospitals for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 47